Proteome Sciences PLC - Asset Resilience Ratio

Latest as of December 2005: 19.84%

Proteome Sciences PLC (PRM) has an Asset Resilience Ratio of 19.84% as of December 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PRM current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

GBX1.90 Million
≈ $231.18 USD Cash + Short-term Investments

Total Assets

GBX9.58 Million
≈ $1.17K USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2005)

This chart shows how Proteome Sciences PLC's Asset Resilience Ratio has changed over time. See PRM net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Proteome Sciences PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRM stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX1.90 Million 19.84%
Total Liquid Assets GBX1.90 Million 19.84%

Asset Resilience Insights

  • Good Liquidity Position: Proteome Sciences PLC maintains a healthy 19.84% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Proteome Sciences PLC Industry Peers by Asset Resilience Ratio

Compare Proteome Sciences PLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Eurofins-Cerep SA
PA:ALECR
Diagnostics & Research 6.56%
Inoviq Ltd
AU:IIQ
Diagnostics & Research 56.29%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Imagion Biosystems Ltd
AU:IBX
Diagnostics & Research 150.16%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Annual Asset Resilience Ratio for Proteome Sciences PLC (2001–2005)

The table below shows the annual Asset Resilience Ratio data for Proteome Sciences PLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2005-12-31 19.84% GBX1.90 Million
≈ $231.18
GBX9.57 Million
≈ $1.17K
+2.44pp
2004-12-31 17.40% GBX1.80 Million
≈ $219.01
GBX10.34 Million
≈ $1.26K
-15.83pp
2003-12-31 33.24% GBX4.79 Million
≈ $583.41
GBX14.43 Million
≈ $1.76K
+9.01pp
2002-12-31 24.23% GBX3.35 Million
≈ $407.51
GBX13.83 Million
≈ $1.68K
+18.22pp
2001-12-31 6.00% GBX225.00K
≈ $27.38
GBX3.75 Million
≈ $455.90
--
pp = percentage points

About Proteome Sciences PLC

LSE:PRM UK Diagnostics & Research
Market Cap
$71.69K
GBX589.22 Million GBX
Market Cap Rank
#31054 Global
#1151 in UK
Share Price
GBX1.68
Change (1 day)
+12.00%
52-Week Range
GBX1.28 - GBX4.05
All Time High
GBX22.25
About

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more